A Comparison Study of Efficacy and Safety of a Biosimilar Form of Intramuscular Βeta-interferon I-a Versus the Reference Product: A Randomized Controlled Clinical Trial in Iran.

Iran J Pharm Res 2019 ;18(3):1632-1638

Department of Neurology, Faculty of Medical, Tehran University of Medical Sciences, Tehran, Iran.

We compared the efficacy and safety of a biosimilar form of beta-interferon-1a (Actovex) versus the reference product in the treatment of relapsing remitting multiple sclerosis (RRMS). In a double blind, randomized phase 3 clinical trial, we evaluated 138 patients with RRMS that were allocated to receive the biosimilar medication and the reference treatment (30 μg intramuscular, weekly for one year). We investigated changes in EDSS, relapse rate and MRI changes within one year. In sixty-nine patients who were allocated to each arm and analyzed mean age and its standard deviation was 32.4 ± 8.8 and 31.5 ± 8 for the biosimilar medication and the reference arm respectively. One-year follow-up revealed a mean difference of 0.084 in EDSS (95% CI: 0.069-0.237) between the two groups in favor of the biosimilar medication. This value did not exceed the predefined non-inferiority margin of 0.1. There were no statistically significant differences in relapse rate and systemic and local adverse events of the two groups. The results show that the biosimilar interferon 1-a is non-inferior to the reference product in terms of efficacy while it demonstrates comparable safety. In conclusion the biosimilar interferon 1-a can be considered as an effective and safe alternative to the reference product due to lower cost and more availability.

Download full-text PDF

Source
http://dx.doi.org/10.22037/ijpr.2019.14503.12441DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934945PMC
January 2019

Publication Analysis

Top Keywords

reference product
16
biosimilar medication
12
biosimilar form
8
clinical trial
8
relapse rate
8
safety biosimilar
8
versus reference
8
interferon 1-a
8
medication reference
8
biosimilar interferon
8
efficacy safety
8
biosimilar
7
reference
6
315 biosimilar
4
deviation 324
4
standard deviation
4
324 315
4
follow-up revealed
4
0084 edss
4
edss 95%
4

Similar Publications